BRIEF-Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic Priorities
Reuters
Jan 09
BRIEF-Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic Priorities
Jan 9 (Reuters) - NewAmsterdam Pharma Company NV KH6.F:
NEWAMSTERDAM PHARMA HIGHLIGHTS 2025 ACHIEVEMENTS AND OUTLINES 2026 STRATEGIC PRIORITIES
NEWAMSTERDAM PHARMA COMPANY NV - EMA APPROVAL DECISION FOR OBICETRAPIB EXPECTED IN H2 2026
NEWAMSTERDAM PHARMA COMPANY NV - RUBENS PHASE 3 TRIAL EXPECTED TO ENROLL APPROXIMATELY 300 PATIENTS, WITH TOPLINE DATA EXPECTED BY YEAR END 2026
Source text: ID:nGNX5PcsMG
Further company coverage: KH6.F
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.